1. In Vivo
  2. >>Global Vision

Minvasys: Tailoring the Stent to Fit the Lesion in Bifurcations

Bifurcated lesions remain one of the most challenging unmet clinical needs facing interventional cardiologists, even with current drug-eluting stents. Here's how one small company is challenging bigger players in this promising market by developing polymer-free DES designed specifically for these difficult bifurcated lesions.

For all the success that drug-eluting stents (DES) have had in treating restenosis (late-stent thrombosis safety issues notwithstanding), certain types of vascular disease remain challenges for interventional cardiologists, even with the current-generation of DES. These include chronic total occlusions, and small and tortuous diseased vessels. One of the largest areas of unmet clinical need exists in patients with bifurcated lesions, where restenosis occurs at a point at which vessels divide into a Y-shape, with a side branch that is more than 2 mm in diameter coming off the main vessel.

Bifurcated lesions occur in an estimated 20 to 30% of all percutaneous coronary interventions (PCI). They are currently treated largely...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

More from In Vivo

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By David Wild

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.